

Welcome to California COVID-19 Vaccination Program Friday Provider Office Hours



Friday, July 15, 2022

Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at:
<https://eziz.org/covid/education/>



If you have post-webinar questions, please email leslie.amani@cdph.ca.gov

Agenda: Friday, July 15, 2022

| No. | Item | Speaker | Time (AM) |
|-----|-------------------------------|--|--------------|
| 1 | Welcome & Announcements | Leslie Amani (Moderator) | 9:00 – 9:05 |
| 2 | Quality Assurance Site Visits | Eugene Beronilla and Francisco Borboa (CDPH) | 9:05 – 9:10 |
| 3 | Vaccine Administration | Elizabeth Reosti (CDPH) | 9:10 – 9:15 |
| 4 | Clinical Update and Poll | Caterina Liu, M.D. (CDPH) | 9:15 – 9:20 |
| Q&A | | | 9:20 – 9:25 |
| 5 | Storage & Handling | Kate McHugh (CDPH) | 9:25 – 9:30 |
| 6 | Vaccine Management | Eric Norton (My Turn) and Maria Volk (CDPH) | 9:30 – 9:40 |
| 7 | KidsVaxGrant 2.0 | Nisha Gandhi (CDPH) | 9:40 – 9:45 |
| 8 | Wrap Up & Resources | Leslie Amani (Moderator) | 9:45 – 10:00 |
| Q&A | | | |

Announcements

Leslie Amani, CDPH

VA58 Bi-weekly Information Digest

This briefing will help you keep up with campaign information.

Digests are released every two weeks and are organized around a specific theme with a focus on actionable insights.

Issue #6 link: [Parent Education: Part 1](#)

Discusses:

- What we all should know about the new vaccines for kids under 5.
- Why vaccines are important for this age group.
- Talking points and tips to better engage with parents.



Updated Talking Points and Test to Treat

Tips for Talking About COVID-19 English & Spanish

Test to Treat English & Spanish

CONSEJOS PARA HABLAR CON OTRAS PERSONAS SOBRE LA VACUNA CONTRA EL COVID-19

¿Ya te vacunaste contra el COVID-19? ¡Que otras personas estén vacunadas contra el COVID-19 nos ayudará a regresar a la normalidad.

La vacuna se ha convertido en parte de nuestras conversaciones diarias. Si bien se puede sentir la necesidad de identificar a las personas a su alrededor por su propia seguridad.

HABLANDO CON TUS AMIGOS

La mejor manera de hablar con tus amigos y familiares sobre la vacuna contra el COVID-19 es compartir tu propia historia. Puedes:

- Por qué decidiste vacunarte
- Qué es lo que significa para ti, incluyendo la protección de los miembros de tu familia y comunidad
- Cómo fue tu experiencia (¿te dolía? ¿te dieron efectos secundarios?)

EL SER UN EXPERTO... O NO

Solo porque estás vacunado, no significa que seas un experto en COVID-19 o la vacunación, y tampoco debes sentirte obligado a responder preguntas o a debatir contigo acerca de los detalles de la vacuna o el virus, puedes decirles:

- "Yo no soy un experto, pero aquí es donde obtuve mi información..."
- "Yo no puedo contestar todas las preguntas, pero si visitas COVID19.ca.gov, hay buena información ahí."
- "Yo solo describo mi experiencia, pero si quieres saber más, habla con tu Doctor."

TIPS FOR TALKING TO OTHERS ABOUT YOUR COVID-19 VACCINE

Got your COVID-19 vaccine? Great! The more people vaccinated against COVID-19, the quicker we can return to normal life.

The vaccine has become a part of our daily conversations. While it may feel odd when others ask if you're vaccinated, many people feel the need to identify vaccinated people around them for their own safety.

TALKING TO YOUR FRIENDS

The best way to talk to your friends about your COVID-19 vaccine experience is simply to tell your own story. You can share:

- Why you got your vaccine
- What it means to you, including protecting family members and the community
- What your experience was like (Did it hurt? Did you have side effects?)

BEING AN EXPERT ... NOT

Just because you are vaccinated, it does not mean you are an expert on COVID-19 or the vaccination – and you don't need to be! If people ask you (or want to debate with you) about vaccine details or the virus, you can tell them:

- "I'm not an expert, but here's where I got my information..."
- "I can't answer all your questions, but if you visit COVID19.ca.gov, there's good information there."
- "I can only describe my experience, but if you want to know more, talk to your doctor."

GUARDIAN PERMISSION

Those under age 18 in California need guardian permission to get the COVID-19 vaccine. Some guardians won't allow their children to get the COVID-19 vaccine due to a lack of trust in vaccines or worry about the COVID-19 vaccine specifically. You can tell a friend who is trying to convince their guardians:

- Provide resources that your own guardians used to make the decision to get you vaccinated.
- Suggest that they:
 - 1) listen to their guardian's concerns
 - 2) share their personal feelings on why they want the vaccine
 - 3) share factual information on the vaccine (check cdc.ca.gov or COVID19.ca.gov)
- Offer to have your guardians talk to their guardians.
- Provide positive support – your friends may not be able to be vaccinated, so be sure you encourage them to wear masks and wash their hands regularly. It's hard to have disagreements with our guardians, and these can lead to stress and pain.

RESOURCES

Here are some resources you or your friends can use:

- Your doctor
- VaxTeen.org
- CDC.gov
- COVID19.ca.gov
- myturn.ca.gov

Para programar tu vacuna, visita MyTurn.ca.gov o llama al (833) 422-4255

To schedule your vaccine, visit MyTurn.ca.gov or call (833) 422-4255

COVID-19 TEST TO TREAT

WHERE CAN I GET TREATED?

Visit <https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/>

WHAT IS TEST TO TREAT?

"One-Stop Test to Treat" is a faster, easier way to get COVID-19 treatments. You can receive a prescription and get your treatment at one location.

WHAT TREATMENTS ARE AVAILABLE?

COVID-19 treatments include two oral pills – Pfizer's Paxlovid and Merck's Lagevrio (molnupiravir) – that can help prevent illness and hospitalization when taken soon after symptom onset. To be eligible, you must be positive and have symptoms that started five days or fewer. You must also be at risk of developing severe COVID-19.

PRUEBA PARA TRATAR

¿DÓNDE PUEDO RECIBIR TRATAMIENTO?

Visita <https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/>

Llama al 1-800-232-0233 para encontrar un sitio de Prueba para Tratar cerca de ti para hacerte la prueba y recibir tratamiento.

¿QUÉ ES PRUEBA PARA TRATAR?

Los sitios de "One-Stop Test to Treat" brindan un acceso más rápido y fácil a los tratamientos COVID-19 que salvan vidas. Comienza por hacerte la prueba de COVID-19. Si la prueba da positivo, puedes recibir y surtir tu receta con ayuda de un proveedor de cuidado de salud, todo en un solo lugar.

¿QUÉ TRATAMIENTOS ESTÁN DISPONIBLES?

Las opciones de tratamiento de COVID-19 incluyen dos pastillas antivirales orales, Paxlovid de Pfizer y Lagevrio de Merck (molnupiravir), que pueden ayudar a prevenir enfermedades severas y hospitalización cuando se toman poco después del inicio de los síntomas. Para ser elegible, debes dar positivo y tener menos de seis días con síntomas. También debes tener un mayor riesgo de desarrollar COVID-19 severo.

VISITA MYTURN.CA.GOV PARA ENCONTRAR UN LUGAR DE VACUNACIÓN CERCA DE TI.

Updated Assets

Available in English and

Spanish

**STAY S.M.A.R.T.E.R
LOVE HARDER**

Enjoy every special moment with your family and loved ones by giving them the ultimate protection against COVID-19.

Vaccinate children 6 months and older and get a second booster for 5 and older for safe family moments that everyone can enjoy together.

Visit myturn.ca.gov or call 1 (833)422-4255 to find a vaccination location near you.



**PROTEGE TU
AMOR**

Disfruta cada momento especial con tu familia y seres queridos protegiéndolos contra el COVID-19.

Vacuna a los niños a partir de los 6 meses y obtén un segundo refuerzo para los niños de 5 años en adelante, para momentos familiares seguros donde todos puedan disfrutar juntos.

Visita myturn.ca.gov para encontrar un sitio de vacunación o llama al 1(833)422-4255.



**STAY S.M.A.R.T.E.R
LOVE HARDER**

Enjoy every special moment with your family and loved ones by giving them the ultimate protection against COVID-19.


Vaccinate children 6 months and older and get a second booster for 5 and older for safe family moments that everyone can enjoy together.

Visit myturn.ca.gov or call 1 (833)422-4255 to find a vaccination location near you.



Virtual Backgrounds

Virtual Backgrounds for Kids 6 months+



Social Assets

[Click for English](#)

HELP PROTECT THE ONES YOU LOVE

READY TO GET YOUR CHILD VACCINATED?

Visit myturn.ca.gov or call **1 (833) 422-4255** to find a vaccination location near you.

THE COVID-19 VACCINE IS RECOMMENDED FOR EVERYONE 6 MONTHS +

FREE

SAFE

HAVE QUESTIONS?

Please discuss any questions or concerns you have about the vaccine with your child's pediatrician or visit myturn.ca.gov to learn more.

Vaccinate ALL 58

[Click for Spanish](#)

AYUDA A PROTEGER A LOS QUE AMAS

¿LISTO PARA VACUNAR A TUS HIJOS?

Visita myturn.ca.gov o llama al **1 (833) 422-4255** para encontrar el punto de vacunación más cercano.

¿TIENES PREGUNTAS?

Habla con el pediatra de tus hijos para aclarar cualquier pregunta o duda que tengas sobre la vacuna o visita MyTurn.ca.gov para obtener más información.

LAS VACUNAS CONTRA EL COVID-19 ESTÁN RECOMENDADAS PARA TODAS LAS PERSONAS DE 6 MESES EN ADELANTE

GRATIS

SEGURAS

Vaccinate ALL 58

SMARTER Protective Layers




No single intervention is perfect at preventing the spread of COVID-19.

However, the more **“SMARTER Steps”** you take, the safer you, your family, and your community are against COVID-19.

SMARTER
Steps Protective Layers >

SHOTS

Get vaccinated and boosted when you are due.



COVID-19 Virus
Misinformation Mouse

MASKS

Wear a mask with good fit and filtration.



COVID-19 Virus
Misinformation Mouse

VENTILATION


Meeting outdoors is safest. Improve ventilation indoors by opening windows and using portable air cleaners.



COVID-19 Virus
Misinformation Mouse

TESTS


Take a COVID-19 test if you have symptoms or had an exposure.



COVID-19 Virus
Misinformation Mouse

ISOLATION


Stay home if you're sick or test positive for COVID-19.



COVID-19 Virus
Misinformation Mouse

TREATMENT

Talk to a health care provider about treatment options if you have symptoms.



COVID-19 Virus
Misinformation Mouse

What is Long COVID?

Long COVID is defined as the presence of a wide range of new, returning, or ongoing health problems experienced by people 4 or more weeks after first being infected with COVID-19 and can remain for 6 months or more.

Many people living with the disease were previously fit & healthy.

Children experience long COVID symptoms similar to adults.

Long COVID can affect people who have experienced mild, severe or even symptom-free COVID-19 infections.

Most common symptoms persisting 6 months

- extreme exhaustion (fatigue)
- problems with memory and concentration (brain fog)

Other common symptoms

- high temperature, cough, headaches, sore throat, changes to sense of smell or taste
- ringing ears, earaches
- feeling sick, diarrhea, stomach aches, loss of appetite
- shortness of breath
- fast heart rate or palpitations
- chest pain or tightness
- dizziness
- joint or muscle pain
- rashes
- depression and anxiety
- difficulty sleeping (insomnia)

Ready to get your child vaccinated?

Please discuss any lingering questions or concerns about the vaccine with your child's pediatrician. Visit myturn.ca.gov or call 1(833) 422-4255 to find a vaccination location near you.

Long COVID in Kids

Covid -19 Risk Comparison for teens (12 years+)

| Not getting vaccinated. | VS | Getting vaccinated. |
|---|----|---|
| Risk of serious illness, hospitalization & death from COVID-19. | | Small risk of serious, rare vaccine side effects including myocarditis and pericarditis (TREATABLE heart problems) - after mRNA COVID-19 vaccination. |
| Risk of serious illness, hospitalization & death from COVID-19 virus variants like Delta | | Choosing NOT to vaccinate teens against COVID-19 is the riskier choice. <p>Visit myturn.ca.gov to find a vaccination location near you or call 1(833)422-4255.</p> |
| Risk of "Long COVID" - a wide range of new/ ongoing health problems that starts approx. 4-5 weeks AFTER COVID-19 infection. | | |
| Risk of Multisystem Inflammatory Syndrome in Children (MIS-C) caused by COVID-19. | | |

Vaccinate ALL 58

Risk Comparison for Teens

COVID-19 Risk Comparison for youth (5-11 years)

| Not getting vaccinated youth (5-11 years) | VS | Getting Vaccinated youth (5-11 years) |
|--|----|---|
| Risk of serious illness, hospitalization & death from COVID-19. | | The side effects of the vaccine are usually mild and can include: <ul style="list-style-type: none"> soreness tiredness headache chills nausea vomiting fever |
| Risk of "Long COVID"- a wide range of new/ ongoing health problems that starts approx. 4-5 weeks AFTER COVID-19 infection. | | Children may need to take a day or two off from school/ activities to recover from the side effects. |
| Risk of Multisystem Inflammatory Syndrome in Children (MIS-C) caused by COVID-19. | | <p>Millions of youth (5-11 years) have been vaccinated safely</p> <p>1.4 MILLION 40 % California</p> <p>9.9 MILLION 35 % United States</p> <p>Choosing NOT to vaccinate youth against COVID-19 is the riskier choice.</p> |

Vaccinate ALL 58

Ready to get your child vaccinated? Visit myturn.ca.gov or call 1(833) 422-4255 to find a vaccination location near you.

Risk Comparison for Youth

Infant Toddler Toolkit

Available in English and Spanish **Vaccine Schedule**
6 months +

Available in English and Spanish



Vaccine Timing Guide: Pediatric/Adolescent/Adult

COVID-19 Vaccine Timing–Pediatric

Routine Schedule

| Age | Vaccine | Primary Doses | Booster Dose |
|------------------|------------------------|--|--------------|
| 6 months–4 years | Pfizer–Infant/Toddler | 1st Dose → 3–8 weeks* → 2nd Dose → ≥8 weeks → 3rd Dose | |
| 6 months–5 years | Moderna–Infant/Toddler | 1st Dose → 4–8 weeks* → 2nd Dose | |
| 5–11 years | Pfizer–Pediatric | 1st Dose → 3–8 weeks* → 2nd Dose → ≥5 months → Booster | |
| 6–11 years | Moderna–Pediatric | 1st Dose → 4–8 weeks* → 2nd Dose | |

Schedule if Moderately or Severely Immunocompromised

| Age | Vaccine | Primary Doses | Booster Dose |
|------------------|------------------------|---|--------------|
| 6 months–4 years | Pfizer–Infant/Toddler | 1st Dose → 3 weeks → 2nd Dose → ≥8 weeks → 3rd Dose | |
| 6 months–5 years | Moderna–Infant/Toddler | 1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose | |
| 5–11 years | Pfizer–Pediatric | 1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥3 months → Booster | |
| 6–11 years | Moderna–Pediatric | 1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose | |

^ An 8-week interval may be preferable for some people, especially for males 12–39 years.
View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.

California COVID-19 Vaccination Program IMM-1396 (6/28/22) Page 1 of 3

COVID-19 Vaccine Timing–Adolescent/Adult

Routine Schedule

| Age | Vaccine | Primary Doses | Booster Doses |
|-------|---|--|---------------|
| 12–17 | Moderna–Adol/Adult | 1st Dose → 4–8 weeks* → 2nd Dose | |
| 12+ | Pfizer/Adol/Adult | 1st Dose → 3–8 weeks* → 2nd Dose → ≥5 months → 1st Booster | 2nd Booster |
| 18+ | Moderna–Adol/Adult | 1st Dose → 4–8 weeks* → 2nd Dose → ≥5 months → 1st Booster | 2nd Booster |
| 18+ | Janssen (J&J) Pfizer/Moderna preferred* | 1st Dose → ≥2 months → 1st Booster | 2nd Booster |

Booster Details:

- 1st Booster:**
 - Ages 12–17: Pfizer
 - 18+: Moderna/ Pfizer (mRNA preferred) or J&J*
- 2nd Booster:**
 - Ages 50+: Moderna/Pfizer
 - 18–49: Not currently recommended. (If received J&J for primary and 1st booster, may consider receiving a 2nd booster of mRNA vaccine.)

^ An 8-week interval may be preferable for some people, especially for males 12–39 years.
* Although use of mRNA COVID-19 vaccines is preferred, the Janssen vaccine may be offered in [some situations](#).
View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.

California COVID-19 Vaccination Program IMM-1396 (6/28/22) Page 2 of 3

California COVID-19 Vaccination Program IMM-1396 (6/28/22) Page 3 of 3

Calendario de la Vacuna: Pediátrico/Adolescente/Adulto

Updated

Calendario de la Vacuna COVID-19: Pediátrico



Calendario Rutinario

| Edad | Vacuna | Dosis Primarias | Dosis de Refuerzo |
|----------------|------------------------------|--|-------------------|
| 6 meses-4 años | Pfizer-Bebés/Niños Pequeños | 1ra Dosis → 3-8 semanas → 2da Dosis → ≥8 semanas → 3ra Dosis | |
| 6 meses-5 años | Moderna-Bebés/Niños Pequeños | 1ra Dosis → 4-8 semanas → 2da Dosis | |
| 5-11 años | Pfizer-Pediátrico | 1ra Dosis → 3-8 semanas → 2da Dosis → ≥5 meses → Refuerzo | |
| 6-11 años | Moderna-Pediátrico | 1ra Dosis → 4-8 semanas → 2da Dosis | |

Calendario si está Moderadamente o Gravemente Inmunocomprometido

| Edad | Vacuna | Dosis Primarias | Dosis de Refuerzo |
|----------------|------------------------------|--|-------------------|
| 6 meses-4 años | Pfizer-Bebés/Niños Pequeños | 1ra Dosis → 3 semanas → 2da Dosis → ≥8 semanas → 3ra Dosis | |
| 6 meses-5 años | Moderna-Bebés/Niños Pequeños | 1ra Dosis → 4 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis | |
| 5-11 años | Pfizer-Pediátrico | 1ra Dosis → 3 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → ≥3 meses → Refuerzo | |
| 6-11 años | Moderna-Pediátrico | 1ra Dosis → 4 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis | |

^ Un intervalo de 8 semanas puede ser preferible para algunas personas, especialmente para hombres de 12 a 39 años.

Consulte las [Consideraciones Clínicas Provisionales para el uso de Vacunas Contra el COVID-19](#) para obtener más información. El calendario está sujeto a cambios.

California COVID-19 Vaccination Program

IMM-1396S (7/8/22) Página 1 de 3

Calendario de la Vacuna COVID-19: Adolescente / Adulto



Calendario Rutinario


| Edad | Vacuna | Dosis Primarias | Dosis de Refuerzo |
|-------|---|---|------------------------------|
| 12-17 | Moderna-Adol/Adulto | 1ra Dosis → 4-8 semanas → 2da Dosis | |
| 12+ | Pfizer/Adol/Adulto | 1ra Dosis → 3-8 semanas → 2da Dosis → ≥5 meses → 1er Refuerzo | Edades 12-17: Pfizer |
| 18+ | Moderna-Adol/Adulto | 1ra Dosis → 4-8 semanas → 2da Dosis → ≥5 meses → 1er Refuerzo | Edades 12-17: Moderna/Pfizer |
| 18+ | Janssen (J&J) Pfizer/Moderna preferido* | 1ra Dosis → ≥2 meses → 1er Refuerzo | Edades 12-17: Pfizer |

^ Un intervalo de 8 semanas puede ser preferible para algunas personas, especialmente para hombres de 12 a 39 años.

* Aunque se prefiere el uso de vacunas mRNA COVID-19, la vacuna Janssen se puede ofrecer en [algunas situaciones](#). Consulte las [Consideraciones Clínicas Provisionales para el uso de Vacunas contra el COVID-19](#) para obtener más información. El calendario está sujeto a cambios.

California COVID-19 Vaccination Program

IMM-1396S (7/8/22) Página 2 de 3




* Aunque se prefiere el uso de vacunas ARNm COVID-19, la vacuna Janssen se puede ofrecer en [algunas situaciones](#).


Consulte las [Consideraciones Clínicas Provisionales para el uso de Vacunas Contra el COVID-19](#) para obtener más información. El calendario está sujeto a cambios.


California COVID-19 Vaccination Program

IMM-1396S (7/8/22) Página 3 de 3

Moderna COVID-19 Vaccines/mRNA 6 Mos.- 17 Yrs.




 State of California—Health and Human Services Agency
California Department of Public Health


GAVIN NEWSOM
Governor

July 8, 2022 IZB-FY-22-23-01

TO: California Providers of Pediatric Services


FROM: Robert Schechter, M.D., Chief 
Center for Infectious Diseases
Division of Communicable Disease Control, Immunization Branch

SUBJECT: Moderna COVID-19 Vaccines, mRNA for children 6 months through 17 years: Preliminary information

HIGHLIGHTS

- Moderna COVID-19 Vaccine is recommended for children 6 months through 17 years of age as a two-dose primary series at varying doses according to age span, given 4-8 weeks apart ([CDPH COVID-19 Vaccine Timing](#)). The vaccine is also authorized for administration of an additional dose at least 4 weeks following the second dose to individuals 6 months through 17 years of age with certain kinds of immunocompromise.
- The vaccines for the pediatric age groups are supplied in multiple dose vials with different colored caps and label borders, depending on the age group ([CDPH COVID-19 Vaccine Product Guide](#)). Formulations for age groups should not be used interchangeably.
- Under initial standards, unopened vials may be stored frozen between -50°C to -15°C (-58°F to 5°F) until the published expiration date or for up to 30 days at 2°C to 8°C (36°F to 46°F) prior to first use.
- The information sheet about the V-safe smartphone safety monitoring system should be provided to parent/guardians, who should be encouraged to participate.
- This letter is intended to provide information common to all formulations of pediatric Moderna COVID-19 vaccine, as well as point out age-specific differences, and links to CDC, CDPH, FDA, and other resources.

Immunization Branch / Division of Communicable Disease Control
850 Marina Bay Parkway, Bldg. P, 2nd Floor, Richmond, CA 94804
(510) 620-3737 • FAX (510) 620-3774 • Internet Address: www.getimmunizedca.org



Letter to Providers of Pediatric Services
From Dr. Robert Schechter,
Center for Infectious Diseases
Division of Communicable Disease Control
Immunization Branch
July 8, 2022

Translated Materials: Moderna Fact Sheets

Translations of the Moderna Fact Sheet for Recipients and Caregivers for 6 months through 5 years of age

| Fact Sheet | Vaccine Recipient Group | Language |
|--|---------------------------|--------------------------|
| HOJA INFORMATIVA PARA RECEPTORES Y CUIDADORES AUTORIZACIÓN DE USO DE EMERGENCIA DE LA VACUNA CONTRA EL COVID-19 DE MODERNA PARA PREVENIR LA ENFERMEDAD DEL CORONAVIRUS 2019 (COVID-19) EN NIÑOS DE 6 MESES A 5 AÑOS (June 17, 2022) | 6 months - 5 years of age | Español (Spanish) |
| 给受种人和监护人情况说明书 针对6个月到5岁的个体预防2019冠状病毒病(COVID-19)的现代COVID-19疫苗紧急使用授权 (June 17, 2022) | 6 months - 5 years of age | 中文 (Chinese, Simplified) |
| 수혜자와 간병인을 위한 팩트 시트 6개월에서 5세 사이의 개인에 코로나 바이러스 질병 2019(COVID-19)를 예방하기 위한 모더나 COVID-19 백신의 긴급 사용 승인 (June 17, 2022) | 6 months - 5 years of age | 한국어 (Korean) |
| FACT SHEET PARA SA MGA TATANGGAP AT MGA NAG-AALAGA EMERGENCY USE AUTHORIZATION NG BAKUNANG MODERNA COVID-19 UPANG MAIWASAN ANG CORONAVIRUS DISEASE 2019 (COVID-19) SA MGA INDIBIDWAL 6 NA BUWAN HANGGANG 5 TAONG GULANG (June 17, 2022) | 6 months - 5 years of age | Tagalog (Tagalog) |
| PHIẾU THỰC TẾ DÀNH CHO NGƯỜI NHẬN VÀ KHÁCH HÀNG KHẨN CẤP SỬ DỤNG SỰ CHO PHÉP CỦA THUỐC THỦ Y MODERNA COVID-19 ĐỂ PHÒNG NGỪA BỆNH LỞ CHÂN LÔNG 2019 (COVID-19) Ở CÁ NHÂN 6 THÁNG QUA 5 TUỔI | 6 months - 5 years of age | Tiếng Việt (Vietnamese) |

Translations of the Moderna Fact Sheet for Recipients and Caregivers for 6 through 11 years of age

| Fact Sheet | Vaccine Recipient Group | Language |
|--|-------------------------|--------------------------|
| HOJA INFORMATIVA PARA RECEPTORES Y CUIDADORES AUTORIZACIÓN DE USO DE EMERGENCIA DE LA VACUNA CONTRA EL COVID-19 DE MODERNA PARA PREVENIR LA ENFERMEDAD DEL CORONAVIRUS 2019 (COVID-19) EN NIÑOS DE 6 AÑOS A 11 AÑOS (June 17, 2022) | 6 - 11 years of age | Español (Spanish) |
| 给受种人和监护人情况说明书 针对6岁到11岁个体预防2019冠状病毒病(COVID-19)的现代COVID-19疫苗紧急使用授权 (June 17, 2022) | 6 - 11 years of age | 中文 (Chinese, Simplified) |
| 수혜자와 간병인을 위한 팩트 시트 6세에서 11세 사이의 개인에 코로나 바이러스 질병 2019(COVID-19)를 예방하기 위한 모더나 COVID-19 백신의 긴급 사용 승인 (June 17, 2022) | 6 - 11 years of age | 한국어 (Korean) |
| FACT SHEET PARA SA MGA TATANGGAP AT MGA NAG-AALAGA EMERGENCY USE AUTHORIZATION NG BAKUNANG MODERNA COVID-19 UPANG MAIWASAN ANG CORONAVIRUS DISEASE 2019 (COVID-19) SA MGA 6 NA TAON HANGGANG 11 TAONG GULANG (June 17, 2022) | 6 - 11 years of age | Tagalog (Tagalog) |
| PHIẾU THỰC TẾ DÀNH CHO NGƯỜI NHẬN VÀ KHÁCH HÀNG KHẨN CẤP SỬ DỤNG SỰ CHO PHÉP CỦA THUỐC THỦ Y MODERNA COVID-19 ĐỂ PHÒNG NGỪA BỆNH LỞ CHÂN LÔNG 2019 (COVID-19) Ở CÁ NHÂN 6 TUỔI QUA 11 TUỔI | 6 - 11 years of age | Tiếng Việt (Vietnamese) |

Translated Materials: Pfizer-BioNTech Fact Sheets

| Translations of the Pfizer-BioNTech Fact Sheet for Recipients and Caregivers for 6 months through 4 years of age | | | the Pfizer-BioNTech Fact Sheet for Recipients and 5 through 11 years of age | | | f the Pfizer-BioNTech Fact Sheet for Recipients and 12 years of age and older | | |
|--|---------------------------|--------------------------|---|-------------------------|--------------------------|--|---------------------------|--------------------------|
| Fact Sheet | Vaccine Recipient Group | Language | | Vaccine Recipient Group | Language | | Vaccine Recipient Group | Language |
| HOJA INFORMATIVA PARA RECEPTORES Y CUIDADORES SOBRE LA VACUNA CONTRA EL COVID-19 DE PFIZER-BIONTECH PARA PREVENIR LA ENFERMEDAD DEL CORONAVIRUS 2019 (COVID-19) PARA USO EN NIÑOS DE 6 MESES A 4 AÑOS (June 17, 2022) | 6 months - 4 years of age | Español (Spanish) | CUNAS PARA RECEPTORES Y CUIDADORES ER-BIONTECH CONTRA EL COVID-19 PARA O DEL CORONAVIRUS 2019 (COVID-19) PARA 11 AÑOS | 5 - 11 years of age | Español (Spanish) | ACUNAS PARA RECEPTORES Y CUIDADORES INA DE ARNm CONTRA EL COVID-19) Y LA ECH CONTRA EL COVID-19 PARA PREVENIR ONAVIRUS 2019 (COVID-19) PARA USO EN MÁS | 12 years of age and older | Español (Spanish) |
| 面向 6 个月至 4 岁的个体使用的用于预防 2019 年冠状病毒病 (COVID-19) 的辉瑞生物技术 COVID-19 疫苗的受种者和监护人员情况说明书 (June 17, 2022) | 6 months - 4 years | 中文 (Chinese, Simplified) | 关于用于预防2019新冠肺炎 (COVID-19) 新冠肺炎疫苗以个人使用的信息概况说 | 5 - 11 years of age | 中文 (Chinese, Simplified) | 酸新冠肺炎疫苗)以及辉瑞-BioNTech2019新肺炎的接受者和护理者须知 | 12 years of age and older | 中文 (Chinese, Simplified) |
| 6개월에서 4세 사이의 개인에 사용하기 위한 2019 코로나 바이러스 질병 (COVID-19) 예방을 위한 화이자-바이오엔텍 COVID-19 백신에 대한 수혜자 및 간병인을 위한 팩트 시트 (June 17, 2022) | 6 months - 4 years | 한국어 (Korean) | 는사람들에게 코로나바이러스감염증 2019 한화이자 (PFIZER)-바이오엔텍 (BIONTECH) 자와 의료진을 위한 백신 정보지 | 5 - 11 years of age | 한국어 (Korean) | 2019 (COVID-19)를 예방하기 위한 코델나티 RNA)와 화이자 (PFIZER)-바이오엔텍 신에 대한 환자와 의료진을 위한 백신 정보 | 12 years of age and older | 한국어 (Korean) |
| FACT SHEET PARA SA MGA TATANGGAP AT MGA NAG-AALAGA TUNGKOL SA BAKUNANG PFIZER-BIONTECH COVID-19 UPANG MAIWASAN ANG CORONAVIRUS DISEASE 2019 (COVID-19) PARA SA PAGGAMIT SA MGA INDIBIDWAL 6 NA BUWAN HANGGANG 4 NA TAONG GULANG (June 17, 2022) | 6 months - 4 years | Tagalog (Tagalog) | ACT SHEET PARA SA MGA TUMANGGAP AT GKOL SA PFIZER-BIONTECH COVID-19 N ANG CORONAVIRUS DISEASE 2019 (COVID- MGA INDIBIDWAL 5 HANGGANG 11 TAONG | 5 - 11 years of age | Tagalog (Tagalog) | SYON SA BAKUNA PARA SA MGA TANGGAP SA COMIRNATY (COVID-19 VACCINE, ZER-BIONTECH COVID-19 UPANG MAIWASAN SE 2019 (COVID-19) | 12 years of age and older | Tagalog (Tagalog) |
| PHIẾU THỰC TẾ DÀNH CHO NGƯỜI NHẬN VÀ NGƯỜI CHĂM SÓC VỀ THUỐC CHỮA BỆNH PFIZER-BIONTECH COVID-19 ĐỂ PHÒNG NGỪA BỆNH HẠI LÃO HÓA 2019 (COVID-19) ĐỂ SỬ DỤNG CHO CẢ NHÂN 6 THÁNG QUA 4 TUỔI (June 17, 2022) | 6 months - 4 years | Tiếng Việt (Vietnamese) | XIN DÀNH CHO NGƯỜI NHẬN VÀ NGƯỜI IZER-BIONTECH COVID-19 NHẪM PHÒNG S 2019 (COVID-19) ĐỂ SỬ DỤNG CHO CẢ | 5 - 11 years of age | Tiếng Việt (Vietnamese) | VỀ VẮC XIN DÀNH CHO NGƯỜI NHẬN VÀ OMIRNATY (VẮC XIN COVID-19, mRNA)VÀ VẮC ID-19 ĐỂ PHÒNG NGỪA BỆNH D-19) | 12 years of age and older | Tiếng Việt (Vietnamese) |

Job Aid: Administration Errors

Links to:

- Administration Checklist
- CDC's Interim Clinical Considerations
- CAIR/RIDE information
- VAERS (Vaccine Adverse Event Reporting System)
- VERP (Vaccine Errors Reporting Program)

Responding to Administration Errors

California COVID-19 Vaccination Program



Incorporate [this administration checklist](#) into practice protocols to help ensure your patients receive sufficient protection after vaccination and to minimize revaccination efforts due to administration errors.

Instructions

Follow these instructions to respond to administration errors following CDC requirements.

| Step | Description |
|------|--|
| 1. | Inform the recipient of the vaccine administration error. |
| 2. | Refer to CDC's Interim Clinical Considerations (Appendix C) to determine whether revaccination may be recommended. Contact the manufacturer for any questions. <ul style="list-style-type: none">• Moderna: 1-866-MODERNA (1-866-663-3762)• Pfizer: Call 800-438-1985• Janssen: 1-800-Janssen (1-800-526-7736) |
| 3. | Contact your local CAIR2/RIDE representative to determine how the dose should be entered into the CAIR, both as an administered dose and to account for inventory. |
| 4. | Report all COVID-19 vaccine administration errors to VAERS—even those not associated with an adverse event. <ul style="list-style-type: none">• To file an electronic report, please see the VAERS website.• Reporting to VERP is not required but strongly encouraged to help prevent future errors or patient harm. |
| 5. | Determine how the error occurred and implement strategies (e.g., education/training) to prevent it from happening again. Tip. Use this guidance to prevent administration errors from occurring again. |

California COVID-19 Vaccination Program

IMM-1426 (7/12/22)

Stay informed!

Provider Resources on eziz.org/covid

Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!

**Vaccinate
ALL 58**

California COVID-19 Vaccination Program

ENHANCED BY Google

Program Updates

Program Enrollment

My Turn Onboarding

Vaccine Management

Vaccine Administration

Reporting Requirements

Archived Communications

Patient Resources

Updates for Providers


FAQs


Provider
Office Hours


Training


Training
Calendar

Alerts:

Infant/Toddler Recommendations and Products

- [Guide of COVID-19 Vaccine Products](#)
- Summary of Vaccines: [Pfizer 6 months-4 years](#) and [Moderna 6 months-5 years](#) (CDPH)

Vaccine Administration

- [Interim Clinical Considerations for Use of COVID-19 Vaccines \(CDC\)](#)
- [COVID-19 Vaccination Schedule \(Timing Guide\)](#)—CDPH version back by popular demand!
Spanish version: [Calendario de la Vacuna COVID-19 \(Guía de Tiempo\)](#)
- Children who transition from a younger to an older age group: [Pfizer-BioNTech](#) | [Moderna](#)

Planning Resources

- [Preparing for Infant/Toddler Vaccinations Job Aid](#)
- [Planning for Under 5 Vaccinations Webinar Recording and Slides](#)
- [Recommending COVID-19 Vaccination: Clinical Talking Points 6/17/22](#)
- [Requesting COVID-19 Vaccination Staff](#)
- [Expanding Vaccination Capacity](#)

Now Enrolling Providers of Pediatric Services

- [Find Information on How to Enroll](#)
- [Dispelling Provider Myths About Joining the California COVID-19 Vaccination Program](#)
- [Welcome VFC Providers](#) | [Flyer](#) | [VFC vs. COVID Programs](#)

Provider Support

COVID Call Center

Email: [Program Info](#)
Phone: (833) 502-1245
Hours: Mon-Fri, 8AM-6PM

Contact us for questions about the program or help with accessing documents.

myCAvax and My Turn

Email:
[myCAvax Technical Support](#)
[MyTurn Onboarding](#),
[MyTurn Technical Support](#)
Phone: (833) 502-1245
Mon-Fri, 7AM-7PM
Sat-Sun, 8AM-1PM

My Turn Clinic Translation Line:
(833) 980-3933
Mon-Fri: 8AM-8PM
Sun-Sat: 8AM-5PM

COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated weekly: last updated 07/14/2022
- Currently in its 80th iteration!



Q: Are the Pfizer and Moderna COVID-19 vaccine fact sheets for providers and recipients/caregivers available in non-English languages?

A: Yes. The Pfizer and Moderna COVID-19 vaccine fact sheets for providers and recipients/caregivers, including those for the infant/toddler vaccines, are available in Spanish, Chinese, Korean, Tagalog, and Vietnamese. Please access the Pfizer fact sheets [here](#) and the Moderna fact sheets [here](#).



Q: Will the Novavax COVID-19 vaccine be available to order through the CA COVID-19 Vaccination Program?

A: On July 11, 2022, Novavax announced that the U.S. federal government [purchased 3.2 million doses of the Novavax COVID-19 vaccine](#). On July 13, [the FDA authorized emergency use of the Novavax COVID-19 vaccine](#). CDC, and Western States Scientific Safety Review Workgroup recommendations are pending. CDPH will continue to provide updates regarding Novavax COVID-19 vaccine ordering.

California COVID-19 Vaccination Program Provider FAQs

For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers. Providers may also visit [California COVID-19 Vaccination Program](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

Contents

| | |
|-----------------------------------|----|
| New and Updated FAQs | 2 |
| Pediatric Providers | 2 |
| Vaccine Program Management..... | 3 |
| Provider Enrollment | 4 |
| Ordering..... | 4 |
| Distribution/Redistribution | 4 |
| Vaccine Administration | 5 |
| Additional/Booster Doses | 8 |
| Vaccine Storage & Handling..... | 9 |
| Inventory..... | 10 |
| Reporting | 10 |
| Billing & Reimbursement | 11 |
| Communication Resources | 12 |

[Provider FAQs on EZIZ, Updated Weekly](#)



Vaccinate ALL 58

Pfizer COVID-19 Vaccine Updates & Trainings

| Date & Time (linked) | Password |
|--|-------------|
| Tuesday, July 19 - 12PM | PaHyM9KpY45 |
| Wednesday, July 20 - 9AM | EpBS3gMJW33 |
| Thursday, July 21 - 9AM | CmxXckkJ659 |
| Tuesday, July 26 - 12PM | BVqKcg25GQ4 |
| Wednesday, July 27 - 9AM | aU7BRQ8tTZ7 |
| Thursday, July 28 - 9AM | W9jxbB6MnT4 |
| <p>More sessions listed!</p> <p>NOTE: All times listed here are PDT.</p> | |

Audience:

Providers and immunization staff

Session Topics Include:

- New vaccine presentation (**Maroon Cap**) for individuals 6 months through 4 years of age** (Starting June 7)
- FDA approvals, authorizations - including recent authorizations
- **Gray Cap**, Comirnaty®
- Use of each vaccine presentation, including storage, handling, preparation, and administration



Moderna Infant/Toddler Vaccine Video Trainings



Link to Video Resources



[How to Withdraw a 0.25mL dose: Infant/Toddler 6 months-5 years](#)



[How to Withdraw a 0.5mL Dose for Pediatrics 6 Years-11Years](#)

US-COV-2200159 06/2022

Week of July 18, 2022

Note: Calendar subject to change

| | Monday 7/18 | Tuesday 7/19 | Wednesday 7/20 | Thursday 7/21 | Friday 7/22 |
|--|-------------|--|---|---|---|
| myCAvax, My Turn, and Combined Office Hours and Events | | Pfizer BioNTech COVID-19 Vaccine Training & Education* 12:00 pm – 1:00 pm PW: PaHyM9KpY45 What's New in myCAvax 12:30 pm – 1:00 pm | Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: EpBS3gMJW33 | Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: CmxXckkJ659 | Provider Office Hours 9:00 am – 10:00 am |

* Pfizer topics vary by day and include the latest information about use of each vaccine presentation, including storage, handling, preparation, and administration; recent medical updates and FDA authorizations, healthcare provider resources, and a Q&A session.

| | | | |
|----------------|--|--|--|
| View On Demand | <ul style="list-style-type: none">Intro to My Turn Onboarding (v. 1/4/22)Latest Features in My Turn (*Requires My Turn Login) | <ul style="list-style-type: none">Latest Features in myCAvax for Providers (*Requires myCAvax Login)myCAvax Release Notes for LHJs and CDPH Users (*Requires myCAvax Login)COVID-19 Crucial Conversations Archived Webinars and Slides | <ul style="list-style-type: none">Provider 101 Account Enrollment: Section A: Organization Application (v. 10/21/21)Provider 101 Account Enrollment: Section B: Location Application (v. 10/21/21)Provider Office Hours and MCE Office Hours Archived Sessions |
|----------------|--|--|--|

Help

Website: www.eziz.org/covid, [FAQs](#)
General email: covidcallcenter@cdph.ca.gov
CDPH Provider Call Center: 1-833-502-1245, 8am-6pm

My Turn email: myturnonboarding@cdph.ca.gov
myCAvax Help Desk Email: myCAvax.HD@accenture.com
Phone: (833) 502-1245

Quality Assurance Site Visits

Eugene Beronilla and Francisco Borboa (CDPH)

COVID VACCINE QA (Quality Assurance) UPDATE: PROVIDER AGREEMENT REQUIREMENTS




“COVID-19 vaccination providers and depot locations that store or redistribute COVID-19 vaccine must accommodate these (awardee) staff and participate in COVID-19 quality assurance site visits and other educational opportunities associated with COVID-19 vaccination program requirements.”


Per the section

“UPDATES - CDC COVID-19 Vaccination Program Provider Agreement Requirements”

COVID VACCINE QA UPDATE: REGIONS, DELIVERABLES, & PROGRESS



COVID VACCINE QA UPDATE: TOP FIVE NONCOMPLIANT AREAS IDENTIFIED DURING QA VISIT




- 1 Documenting/reporting Spoiled, Expired, and Wasted Vaccine
- 2 Vaccine Administration
- 3 Billing Documentation
- 4 Ancillary Supply Kits
- 5 Documenting/reporting Temperature Excursions

Source: REDCap data report as of June 30, 2022

COVID VACCINE QA UPDATE: DORMITORY (DORM) STYLE REFRIGERATOR UNITS

— The use of dormitory style or dorm units is not safe for vaccines!

Inconsistent temperatures and the creation of frost or ice on cooling plates can damage the viability of the vaccines




Vaccine Administration Data

Elizabeth Reosti, CDPH

Vaccine Administration Summary


as of July 11, 2022



77,851,959

Total Doses Administered:

Daily Doses Administered: **Statewide**



Trends in Vaccine Administration

as of July 11, 2022

New Eligibility Groups Driving Demand


- First doses among under 5
- First boosters among 5-11-year-olds
- Second boosters among 50+ year-olds

FDA NEWS RELEASE

Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age

For Immediate Release: June 17, 2022

Weekly Doses Administered by Age Group




| Percent change from previous week | - 2% | - 14% | - 2% | - 4% | - 15% |
|-----------------------------------|-------|-------|-------|-------|-------|
| 5-11 | - 4% | - 14% | - 13% | - 8% | - 16% |
| 12-17 | + 18% | - 4% | - 10% | - 7% | - 14% |
| 18-49 | + 5% | - 8% | - 7% | - 4% | - 13% |
| 50-64 | - 4% | - 14% | - 13% | - 8% | - 8% |
| 65+ | - 6% | - 18% | - 15% | - 13% | - 9% |
| Under 5 | | | | + 32% | - 35% |

5-11-Year-Old Vaccination Trends

as of July 11, 2022

- Slight decrease in first doses among 5-11-year-olds from previous week
- Includes 4th of July holiday week

Weekly New 5-11 year-old Partially Vaccinated Recipients by VEM: **Statewide**



| | Percent Change from Previous Week: | | | | |
|----|------------------------------------|-------|------|------|------|
| | | + 14% | - 1% | + 2% | + 2% |
| Q4 | | + 9% | - 5% | - 5% | + 5% |
| Q3 | | + 13% | - 5% | + 3% | + 4% |
| Q2 | | + 16% | + 5% | + 5% | - 3% |
| Q1 | | + 18% | + 2% | + 5% | + 4% |

Infant/Toddler Vaccinations

- From January to April, about 10% of parents surveyed changed their intention from “get them vaccinated right away” to “wait and see”.
- Parents of infants/toddlers were less likely to say “definitely not” than parents of 5-11-year-olds (27% vs 32%)*

Thinking about your child between the ages of 5 and 11, have they received at least one dose of a COVID-19 vaccine, or not? If not, do you think you will get them vaccinated...?

■ Child is vaccinated ■ Right away ■ Wait and see ■ Only if required ■ Definitely not




*Refer to table for percentages

PARENTS AND KIDS

One In Five Parents Of Children Under Five Say They'll Vaccinate Their Child Right Away Once Available, But Most Remain More Cautious

Thinking about your child under the age of 5, once there is a COVID-19 vaccine authorized and available for your child's age group, do you think you will...?

■ Get them vaccinated right away ■ Wait and see ■ Only if required ■ Definitely not



NOTE: Among parents or guardians of children under the age of 5. See topline for full question wording.


SOURCE: KFF COVID-19 Vaccine Monitor • PNG

KFF COVID-19
Vaccine Monitor

Infant/Toddler Vaccinations

as of July 11, 2022


Slower rollout over the first 19 days of eligibility for youngest eligibility group



Infant/Toddler Vaccinations

as of July 11, 2022


Disparities in
vaccination coverage
rates by Vaccine
Equity Metric Quartile
after first three weeks
of eligibility



Infant/Toddler Vaccinations

as of July 11, 2022

Lower vaccination rates among Black and Latino children after first three weeks




Infant/Toddler Vaccinations

as of July 11, 2022

- Clinical providers increasingly important for reaching younger ages
- Reduced role of pharmacies for youngest age groups

Under 5 Doses by Age and Provider Type



Data Summary

as of July 11, 2022

Latest Metrics

77.9 Million doses administered

204K doses administered in previous week (-15% pt change)

22K new Infant/Toddler recipients (-22% pt change)

System Updates

- Vaccination data for children under 5 years of age added to all dashboards
- 4th doses included in overall dose count, but not currently displayed in immunization status

Clinical Update

Caterina Liu, M.D., CDPH

FDA Grants EUA for Novavax COVID-19 Vaccine

- Emergency Use Authorization (EUA) issued for Novavax COVID-19 vaccine as a primary series in adults 18+
- Novavax COVID-19 vaccine
 - SARS-CoV-2 recombinant spike protein (5 mcg) + Matrix-M adjuvant (50 mcg)
 - Studied in adults 18 years and older
 - Primary series is two 0.5 ml doses given intramuscularly 21 days apart
 - Vials contain 10 doses ready-to-use liquid formulation
 - Stored at 2°- 8° Celsius
- U.S. Government purchasing 3.2 million doses
- ACIP (Advisory Committee on Immunization Practices) will meet next week, 7/19/22

CDC/ACIP Influenza Vaccine Recommendation: Adults 65+

CDC director approved influenza vaccine recommendations by ACIP* in June 22-23, 2022:

- Adults aged ≥ 65 years should preferentially receive one of the following influenza vaccines:
 - Quadrivalent high-dose inactivated influenza vaccine (HD-IIV4)
 - Quadrivalent recombinant influenza vaccine (RIV4), or
 - Quadrivalent adjuvanted inactivated influenza vaccine (aIIV4).
- If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.


*Advisory Committee on Immunization Practices

FDA Approves Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) for 12 through 15-Year-Olds

- 12/11/20: FDA authorized emergency use under Emergency Use Authorization (EUA) of Pfizer-BioNTech COVID-19 mRNA vaccine to prevent COVID-19 in individuals 16 years and older.
- 5/10/21: FDA granted Pfizer COVID-19 vaccine EUA in 12 through 15-year-olds.
- 8/23/21: FDA approved full Biologics License Application (BLA) of COMIRNATY (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
- 7/8/22: FDA approved BLA supplement for COMINARTY use in 12-through-15-year-olds.

MMWR*: COVID-19 Vaccine Provider Availability & Vaccination Coverage for Children 5 through 11 Years Old


- U.S. county-level vaccine administration data 11/2021-4/2022
- 87.5% of counties analyzed had at least one active vaccine provider
 - Approximately half did not have a pediatric, family medicine clinic, or FQHC
 - Most had at least one pharmacy or public health clinic
- Vaccination coverage for 5-11-years-old was higher in counties with ≥ 1 active vaccine provider




*Morbidity and Mortality Weekly Report

Pfizer COVID-19 Vaccine Effectiveness in Children and Adolescents Against Hospitalization for COVID-19

- Case-control, test-negative design of hospitalized pediatric patients in 23 U.S. states
- Total 1185 case patients: 291 (25%) had critical COVID-19, including 14 who died.
- 918 case patients were 12-18-years-old and 267 were 5-11-years-old.



Pfizer VE* in Children and Adolescents Against Hospitalization and Critical Illness (Requiring Life support)



- During Omicron
 - 12-18yo: 40% VE against hospitalization, 79% VE against critical illness
 - 5-11yo: 68% VE against hospitalization (sample size too small for critical illness)

*Vaccine Effectiveness

Long-COVID in Children and Adolescents: A Systematic Review and Meta-analyses

- Review of 21 observational studies conducted prior to Feb 2022 that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID
- Included 80,071 children and adolescents primarily from European countries
- The prevalence of long-COVID was 25.24%.
 - Mood symptoms (16.50%), fatigue (9.66%), sleep disorders (8.42%), headache (7.84%), and respiratory symptoms (7.62%)
- Most symptoms improved with time.
- Risk factors associated with long-COVID in children are similar as in adults.
 - Older age, female, severe COVID-19, overweight/obesity, allergic diseases, and other long-term co-morbidities
- Protective factors
 - Fewer comorbidities, strong innate immune responses, reduced expression of angiotensin-converting enzyme-2 (ACE2) receptors, and active thymic function
 - Range of environmental factors such as vaccines, past infections, nutrition, and/or the gut microbiome

Pooled Prevalence of Long COVID Symptoms

Long-COVID in children and adolescents

25.24%

Neuropsychiatric (%)

- **Mood** 16.50 (sad, tense, angry, anxiety, depression)
- **Fatigue** 9.66
- **Sleep disorder** 8.42 (insomnia, hypersomnia, poor sleep quality)
- **Headache** 7.84
- **Cognition** 6.27 (confusion, impaired concentration, learning difficulties, memory loss)
- **Dizziness** 4.40
- **Neurological abnormalities** 0.86 (pins and needles, tremor, numbness)
- **Balance problems** 0.54

Gastrointestinal (%)



- **Abdominal pain** 2.91
- **Constipation** 2.05
- **Diarrhea** 1.68
- **Vomiting/nausea** 1.53

Cardiorespiratory (%)

- **Respiratory symptoms** 7.62
- **Sputum/nasal congestion** 7.53
- **Orthostatic intolerance** 6.92
- **Exercise intolerance** 5.73
- **Chest pain** 4.62
- **Rhinorrhea** 4.15
- **Cough** 3.80
- **Sore throat** 2.47
- **Chest tightness** 2.45
- **Variations in heart rate** 2.29
- **Palpitations** 1.27

Dermatologic/Teguments (%)

- **Hyperhidrosis** 4.66
- **Dermatologic** 2.61 (dry skin, itchy skin, rashes, hives)
- **Hair loss** 1.17



Poll: CDPH Appreciates Your Feedback!

1. Is there patient or provider demand for Novavax COVID-19 vaccine?

☐ Yes

☐ No

☐ N/A

2. Are you interested in ordering Novavax?

☐ Yes


☐ No

☐ N/A



Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Storage & Handling

Kate McHugh, CDPH

COVID-19 Vaccine Administration Errors

- CDPH will let you know if there is an uptick in administration errors!
- Providers should know what to do if they make an error.
 - Errors can include administering the following:
 - wrong age group
 - incorrect dilution volume
 - incorrect injection volume
 - administering expired vaccine, etc.

COVID-19 Vaccine Administration Errors: Steps

- Steps include:
 - Notifying patient
 - Refer to CDC's [revaccination information](#) to determine if revaccination is necessary
 - Contacting CAIR to determine how this dose should be entered
 - Reporting to VAERS (required)
 - Implement actions to determine why the error occurred and to ensure it does not happen again
- Manufacturers can help determine if vaccine was viable
 - Moderna: 1-866-MODERNA (1-866-663-3762)
 - Pfizer: Call 800-438-1985
 - Janssen: 1-800-Janssen (1-800-526-7736)
- CDPH clinical team: COVIDVaccineClinical@cdph.ca.gov

How soon will Moderna Release Correctly Labeled COVID-19 Vaccine for Ages 6 Years -11 Years?

- In Moderna's EUA, they mention vials with teal labels that will have correct labeling (as opposed to labeling stating for adult booster doses only).
- CDPH has not heard that these vials will be released any time soon.
- Some providers have said they were waiting for those vials, so we want to make sure you know that they are not coming in the immediate future!
- Providers can use the current Moderna "booster" vials with the purple border authorized for ages 6 years through 11 years.

Vaccine Management

Eric Norton, My Turn, and Maria Volk, CDPH

My Turn and myCAvax Office Hours Cadence Reminder



As of Monday July 11th, the Monday My Turn and myCAvax office hour session has been moved to a **bi-weekly** cadence.

To register for the webinar, click [here](#).

My Turn Micro-Videos



Here is a list of the new **My Turn** micro-videos that are now available. [You can find them here.](#)



1. Add a Walk-in Appointment
2. Bulk Upload Walk-in Appointment
3. Cancel and Rebook Appointments
4. Clear a Patient Record
5. Document Adverse Reaction
6. Edit a Patient Record
7. Edit or Bulk Update Appointments
8. Enter Vaccine Administration Data
9. Patient Check-in
10. Search for an Appointment

What's New in myCAvax? - Release 28



New updates for Providers launched July 14th




Providers

- ✓ You can place Location Accounts on temporary closure for holidays or other dates.
- ✓ New thermometer type options are available when adding new storage units in Section B.


Temporary Closure for a Location Account



 **myCAVax**
California Vaccine Management System

Home Enrollment Locations Vaccine Orders Vaccine Inventory

Need Help? Please see the [Managing myCAVax Provider Accounts](#) job aid.


 **Account**
Mickey Mouse Clubhouse

Account Owner

Status

Account Record Type

Type

 [San Francisco County...](#)

Active

Provider Location

DETAILS

RELATED

Friday Open From

07:00 AM

Friday Open To

05:00 PM

Friday Closed From

01:00 PM

Friday Closed To

02:00 PM

▼ Temporary Closure

Temporary Closure Start

7/11/2022

Temporary Closure End

7/15/2022

Providers can place a location in **temporary closure** for holidays or irregular dates. View the **temporary closure** status of your location from the Account tab or on the Vaccine Order screen.



APPENDIX

What's New in myCAvax: Release 28 (07/14)

Account

- ✓ You will be able to place Location Accounts on temporary closure for holidays or other dates.

Enrollment

- ✓ New thermometer type options will be available when adding new storage units in Section B.

myCAvax – Known Issues - *Updated 7/08*

Known Issues




VaccineFinder Data Not Showing on the Multi-Line Ordering Form

- ✓ For some community users, their VaccineFinder data is not being populated when creating new orders through the multi-line ordering form.
- ✓ However, the data is being correctly populated for the LHD users who review the orders on the 'Vaccine Order Review' page

Workaround/Next Steps

- ✓ Fix: July 14th
- ✓ No Workaround for the time being

Slide Icon Key

| Icon | Meaning |
|--|--|
|  | This is to label slides that are referencing upcoming or existing functionality and how to use it in the system. |
|  | This is to label slides that include important system reminders. |
|  | This is to label slides that include tips and best practices to improve your system experience. |

myCAvax Release Roadmap

RECENTLY DEPLOYED

June 16th (R27.0)

Orders

- ✓ LHDs to Move Small Orders to Standard Orders
- ✓ Order Page Layout Changes
- ✓ New order cancellation 'Status Reason' options
- ✓ Update Audit History for Orders/Transfers
- ✓ Add 'Doses Requested' to Standard Order Screen

Account

- ✓ Storing DocuSign at the Location Application

Community

- ✓ Add Knowledge Center article to account page
- ✓ Change Flow Title for Multiple Flows

Other

- ✓ Auto-Deactivate Licenses
- ✓ Default tab display on opening of records
- ✓ Remaining email templates to Lightning

IN PROGRESS

July 14th (R28.0)

Orders

- ✓ Order Fulfillment Updates to allow multiple lots and general UI enhancements
- ✓ Allow CDPH and LHD users to update additional details on the Shipment Records such as quantity, product, expiration date, etc.
- ✓ Validate Shipping Hours
- ✓ Set Flags for Temporary Closure on Vaccine Order Review page

Account

- ✓ Temporary Closure for Location Accounts
- ✓ Add VFC Regions to Accounts
- ✓ Add Calibration Expiration date to Storage Unit List

Community

- ✓ Update Thermometer Type options
- ✓ Add Data Logger as Shipment Incident Type

Site Visits

- ✓ Provider Category
- ✓ VFC Assigned Pin

Other

- ✓ Put LHD Dashboard on LHD Homepage

UPCOMING

August 11th (R29.0)

Orders

- ✓ Draft Order Enhancements

Account

- ✓ Provider initiated Disenrollment
- ✓ Disenrollment due to inactivity

Other

- ✓ Start of Contact enhancements to remove duplicate contacts
- ✓ Sharing Rule enhancements for accounts, storage units, etc.

My Turn Public Product Roadmap

RECENTLY DEPLOYED

June 20th (R27)

Release 28

- ✓ Pfizer Infant/Toddler rollout for 3 dose primary series for children 6 months-4-years old
- ✓ Moderna Infant/Toddler rollout for 2 dose primary series for children 6 months-5-years old
- ✓ [Testing] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ Continued Analysis – Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

RECENTLY DEPLOYED

July 7th (R28.4)

Release 28.4

- ✓ Moderna Pediatric 6-11 and Adolescent 12-17 rollout
- ✓ [Testing] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ Continued Analysis – Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

UPCOMING

July 27th (R29)

Release 29

- ✓ Removing flu – zero out flu vaccine supplies to remove nasal spray and flu shot tags
- ✓ In-home vaccination and transportation page updates to reflect guidance for under 5 patients
- ✓ [Testing] Custom flows for vaccine type
- ✓ [Delivery] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ [Testing] Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

My Turn Clinic Product Roadmap

RECENTLY DEPLOYED

June 20th (R28)

Release 28

- ✓ Moderna Infant/Toddler 6 months-5-years two-dose series
- ✓ Pfizer Infant/Toddler 6 months-4-years three-dose series
 - ✓ Dose Fields Update
 - ✓ Add Vaccine Supply & Inventory
 - ✓ Bulk Walk-In Upload
 - ✓ Clinic Creation Setup
 - ✓ Walk-in Flow Update
 - ✓ Vaccine Administrator Flow Update
 - ✓ Single/Bulk Update
 - ✓ Appointment/IIS Tab Filter Update
 - ✓ Dashboard Homepage Update

RECENTLY DEPLOYED

July 7th (R28.4)

Release 28.4

- ✓ Moderna Pediatric 6-years-11-years two-dose series
- ✓ Moderna Adolescent 12-years-17-years two-dose series
 - ✓ Add Vaccine Supply & Inventory
 - ✓ Bulk Walk-In Upload
 - ✓ Clinic Creation Setup
 - ✓ Walk-in Flow Update
 - ✓ Vaccine Administrator Flow Update
 - ✓ Single/Bulk Update
 - ✓ Appointment/IIS Tab Filter Update
 - ✓ Dashboard Homepage Update

UPCOMING

July 27th (R29)

Release 29

- ✓ [SMS/Email] Opt-out on the Walk-In flow
- ✓ [Vaccine Inventory] Entering Lot Numbers correctly
- ✓ [CAIR2] Concatenate "Cross Street 1" and "Cross Street 2"

KidsVaxGrant 2.0

Nisha Gandhi, CDPH



KidsVaxGrant 2.0 – Coming July 2022!

- The California Department of Public Health has appropriated approximately \$10 million to support KidsVaxGrant 2.0
- Up to \$25,000 to support eligible pediatric providers administering the COVID-19 vaccine to infant/toddler age

More details coming soon!

Bookmark [KidsVaxGrant.org](https://kidsvaxgrant.org) to stay up to date or email us at Kidsvaxgrant@phcdocs.org to be added to our email list



Wrap-up

Leslie Amani, CDPH

Additional Support

Type of Support

Description

Updated 6.6.22



COVID-19 Provider Call Center

The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical providers in California and their COVID-19 response, specifically addressing questions about State program requirements, enrollment, and vaccine distribution, including the Vaccine Marketplace.


- Email: covidcallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–6PM



Enrollment Support

For Provider enrollment support, please contact myCAvax Clinic Operations at

- Email: myCAvaxinfo@cdph.ca.gov




myCAvax Help Desk

Dedicated staff provide up-to-date information and technical support on the myCAvax system.

- Email: myCAvax.HD@Accenture.com
- Phone: (833)-502-1245, option 3, Monday through Friday 8AM–6PM

For training opportunities: <https://eziz.org/covid/education/>




My Turn Clinic Help Desk

For **onboarding support** (those in the process of onboarding): myturnonboarding@cdph.ca.gov

For **technical support** with My Turn Clinic for COVID-19 and flu vaccines: MyTurn.Clinic.HD@Accenture.com or (833) 502-1245, option 4: Monday through Friday 8AM–6PM

For job aids, demos, and training opportunities: flu at <https://eziz.org/covid/myturn/flu/> and COVID at <https://eziz.org/covid/myturn/>



Archived Communications

For archived communications from the COVID-19 Provider Call Center about the California COVID-19 Vaccination Program visit

- Website: [EZIZ Archived Communications](#)

Hear it? Clear It.

If you see or hear of any vaccine-related rumors within the communities you serve, share them with our Trust and Safety team via the CDPH Rumors Inbox.



Trust and Safety Team

Our shared mission is to reduce COVID-19 vaccine hesitancy and increase vaccination across the State of California.



How You Can Help

You are critical in our effort to provide Californians accurate and timely information around COVID-19 vaccination.



Monitor What You See and Hear


Monitor online media and what you hear in your local communities for potential rumors and inaccurate information.

If found, **report** it to **rumors@cdph.ca.gov**

[Contact](#)

Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Thank you!



Monday

My Turn and myCAvax Office Hours

Next session: Monday, July 25, 12PM

Friday

Provider Office Hours

Next session: Friday, July 22, 9AM